Get the Stockscreener App
0.9821
4.65%
-0.0479
Immuron Limited Adr stock is traded at $0.9821, with a volume of 21,295.
It is down -4.65% in the last 24 hours and down -17.47% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
See More
Previous Close:
$1.03
Open:
$1.04
24h Volume:
21,295
Relative Volume:
0.50
Market Cap:
$7.93M
Revenue:
$4.83M
Net Income/Loss:
$-2.99M
P/E Ratio:
-2.0443
EPS:
-0.4804
Net Cash Flow:
$-2.83M
1W Performance:
-9.06%
1M Performance:
-17.47%
6M Performance:
+16.22%
1Y Performance:
-55.36%
1-Day Range:
$0.9541
$1.04
1-Week Range:
$0.9541
$1.10
52-Week Range:
$0.6765
$2.39
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
0.9821 | 7.93M | 4.83M | -2.99M | -2.83M | -0.4804 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immuron Limited Adr Stock (IMRN) Latest News
Immuron (IMRN) Slips 1.83% to $1.07 as Shares Drift Toward Lower SupportMA Cross Alert - https://www.dars.gov.et/
Immuron Limited Subject to Substantial Holder Notice from The Bank of New York Mellon Corporation - Kalkine
With A$9M in cash and no borrowings, Immuron (NASDAQ: IMRN) narrowed its annual loss. - Stock Titan
Kazia Therapeutics Limited (KZIA) stock price, news, quote and history - Yahoo Finance Australia
IMRN - Finviz
symbol__ Stock Quote Price and Forecast - CNN
Immuron (NASDAQ: IMRN) Secures Exclusive U.S. Distribution Rights for PROIBS in $4.16 Billion Digestive Health Market - Kalkine Media
What Does Friday’s Move Mean for Immuron (NASDAQ:IMRN) on Nasdaq? - Kalkine Media
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results - Benzinga
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August - Benzinga
IMRN Stock Jumps As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
IMRN Stock Jumps As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
IMRN Stock Pops As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
$4.16B US gut health market in sight for Immuron (IMRN) with new PROIBS distribution deal - Stock Titan
Immuron (ASX:IMC; NASDAQ:IMRN) Brings European-Certified Medical Device PROIBS® To U.S. Consumers - kalkinemedia.com
Immuron Limited WarrantsADR (IMRNW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss - Stock Titan
Immuron Reports FY26 Preliminary Results - Barchart.com
Kazia Therapeutics LimitedADR Peer Comparison – Compare with Others - Value Research
Immuron (IMRN) Levels: Moves 3.48% Up to $1.19 at the Close; Next Session: the Supplied Trading Band Runs From $1.13 to $1.25 at the CloseValue Area Low - careplusvn.com
Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development - Stock Titan
Immuron (IMRN) Levels: Moves 3.48% Up to $1.19 at the Close; Next Session: the Supplied Trading Band Runs From $1.13 to $1.25 at the CloseLow Vol Factor - dars.gov.et
Immuron (IMRN) Levels: Moves 3.48% Up to $1.19 at the Close; Next Session: the Supplied Trading Band Runs From $1.13 to $1.25 at the CloseThematic ETF Flow - dars.gov.et
Immuron (ASX: IMC) Pushes IMM-529 Forward with FDA Clearance and Partnering Strategy - Kalkine Media
Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference - Stock Titan
Immuron (IMRN) Holds Gains Above $1.10 as Micro-Cap Biotech Finds Buying InterestVolume Spike Alerts - careplusvn.com
Immuron (IMRN) Holds Gains Above $1.10 as Micro-Cap Biotech Finds Buying InterestCash Secured Put - dars.gov.et
Immuron (IMRN) Holds Gains Above $1.10 as Micro-Cap Biotech Finds Buying InterestChannel Breakout - vinanet.vn
PRU Q2 2026 Earnings: EPS Beats Estimates by 14.5% as Prudential Delivers Strong ResultsRevenue Breakdown Analysis - vinanet.vn
Immuron Limited (IMRN) Edges Higher to $1.08, Approaches Key Resistance at $1.13Trade Entry Signals - dars.gov.et
GLIBK Q1 2026 Earnings: EPS Misses Estimates by 63.89%, Coming in at $0.45 per ShareTangible Book Value - vinanet.vn
Immuron Limited (IMRN) Slips 1.8% as ADR Tests Key $1.04 SupportMutual Fund Flow - vinanet.vn
Immuron Limited (IMRN) Slips 1.8% as ADR Tests Key $1.04 SupportLinear Regression - dars.gov.et
Immuron (NASDAQ: IMRN) outlines FY26 growth, cash runway and CDI IND plans - Stock Titan
Immuron Limited Sponsored ADR Revenue Breakdown – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Revenue Breakdown – LSX:A2DTD8 - TradingView
Immuron Limited (NASDAQ: IMRN) highlights antibody platform at TechKnow Invest - Stock Titan
Immuron Limited (NASDAQ: IMRN) grows FY26 revenue to A$7.7m - Stock Titan
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar - Barchart.com
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - Sahm
BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits - Kalkine
Immuron (NASDAQ: IMRN) lifts FY26 Travelan sales 6% to AUD$7.7m - Stock Titan
BNY Mellon Boosts Immuron Stake to 44.61% Through ADR Share Deposits by July 2026 - Kalkine Media
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - GlobeNewswire Inc.
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - Barchart.com
AVANTEL.NS Mar 2026 Earnings: EPS of ₹0.27 on Revenue of ₹63.15 CroreOne-Time Loss Impact - vinanet.vn
Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push - Stock Titan
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):